DepoMed, Inc. (NASDAQ:DEPO)
CAPS Rating:
A specialty pharmaceutical company focused on the development and commercialization of differentiated products that address growing markets and are based on proprietary oral drug delivery technologies.
RSS Headlines
Fool UK
Recs
"Cancer risk" can't see this being a good investment for the next few months at least.
http://www.forbes.com/2010/02/18/xenoport-glaxosmithkline-depomed-markets-equities-pharmaceuticals.html?partner=yahootix